These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 6056940)
21. [EXPERIMENTAL CONTRIBUTIONS ON THE DEMONSTRATION OF INCOMPLETE RH-ANTIBODIES. II. STATISTICAL EVALUATION OF VARIOUS SUPPLEMENTS IN THE DEMONSTRATION OF RH-ANTIBODY]. SCHNEEWEISS B; LANGE A Z Kinderheilkd; 1964 Sep; 90():333-40. PubMed ID: 14316615 [No Abstract] [Full Text] [Related]
22. Inhibition by sera and soluble antigens of T-cell-mediated cytotoxicity against leukaemia-associated antigens. Ting CC; Rogers MJ Nature; 1977 Apr; 266(5604):727-9. PubMed ID: 301609 [No Abstract] [Full Text] [Related]
24. Specificity of antileukemia sera prepared by immunization with leukemia cells admixed with normal antigen-blocking sera. Smith PJ; Robinson CM; Reif AE Cancer Res; 1974 Jan; 34(1):169-75. PubMed ID: 4129197 [No Abstract] [Full Text] [Related]
25. Specificity in the combination of Fd fragments with L chains to form hapten-binding sites. Roholt OA; Radzimski G; Pressman D J Exp Med; 1966 May; 123(5):921-34. PubMed ID: 4161199 [TBL] [Abstract][Full Text] [Related]
26. [EXPERIMENTAL CONTRIBUTIONS ON THE DEMONSTRATION OF INCOMPLETE RH-ANTIBODIES. I. THE INFLUENCE OF THE SUPPLEMENT UPON THE END TITER AND REACTION STRENGTH]. SCHNEEWEISS B; LANGE A Z Kinderheilkd; 1964 Sep; 90():323-32. PubMed ID: 14316614 [No Abstract] [Full Text] [Related]
28. Characterization of the Fv fragment isolated from a human immunoglobulin M. Kakimoto K; Onoue K J Immunol; 1974 Apr; 112(4):1373-82. PubMed ID: 4205527 [No Abstract] [Full Text] [Related]
29. Alloantisera reacting with tumor cells of inappropriate haplotype. I. Characterization of target antigens. Prat M; Rogers MJ; Appella E J Natl Cancer Inst; 1978 Aug; 61(2):527-34. PubMed ID: 79659 [No Abstract] [Full Text] [Related]
30. Purification of murine thymus leukemia antigen (TL). A quantitative assessment of limited proteolysis. Wolcott M; Stanton TH; Williams JL; Bennett JC Biochemistry; 1975 Nov; 14(22):4792-6. PubMed ID: 1182118 [TBL] [Abstract][Full Text] [Related]
31. Further studies on mouse fetal antigen cross-reactive with Rauscher leukemia. Ishimoto A; Suzuki Y; Yoshida T; Ito Y Cancer Res; 1974 Sep; 34(9):2338-43. PubMed ID: 4846102 [No Abstract] [Full Text] [Related]
32. XenCSA: cell surface antigens related to the major glycoproteins (gp70) of xenotropic murine leukemia viruses. Morse HC; Chused TM; Boehm-Truitt M; Mathieson BJ; Sharrow SO; Hartley JW J Immunol; 1979 Feb; 122(2):443-54. PubMed ID: 216748 [No Abstract] [Full Text] [Related]
33. Neutralization of sublines of a mouse leukemia virus with murine antibody, as measured by the spleen focus assay. Sinkovics JG; Pienta RJ; Fiorentino M; Bertin BA Cancer Res; 1967 Jan; 27(1):88-94. PubMed ID: 6020368 [No Abstract] [Full Text] [Related]
34. A quantitative investigation of the G (Gross) antigen in preleukemic and leukemic cells. Wahren B Exp Cell Res; 1966 May; 42(2):230-42. PubMed ID: 5941239 [No Abstract] [Full Text] [Related]
35. Some biochemical properties of thymus leukemia antigens solubilized from cell membranes by papain digestion. Muramatsu T; Nathenson SG; Boyse EA; Old LJ J Exp Med; 1973 May; 137(5):1256-62. PubMed ID: 4540799 [TBL] [Abstract][Full Text] [Related]
36. Lymphocyte-target cell conjugation: membrane receptors for alloantigens. Berke G Adv Exp Med Biol; 1976; 66():483-7. PubMed ID: 1083650 [No Abstract] [Full Text] [Related]